PRODUCT INFORMATION

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic Acid

Item No. 45721



CAS Registry No.: 2654826-81-8
Formal Name: 1-[5-fluoro-1-methyl-3-(tetrahydro-2,4-dioxo-1(2H)-pyrimidinyl)-1H-indazol-6-yl]-4-hydroxy-4-piperidineacetic acid
MF: $C_{19}H_{22}FN_5O_5$
FW: 419.4
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the 2-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid in the solvent of choice, which should be purged with an inert gas. 2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is sparingly soluble (1-10 mg/ml) in DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 2-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid can be prepared by directly dissolving the crystalline solid in aqueous buffers. 2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

2-(1-(3-(2,4-Dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)-4-hydroxypiperidin-4-yl)acetic acid is a proteolysis-targeting chimera (PROTAC) building block.[1] It has been used in the synthesis of a PROTAC that drives mutant B-RAF degradation.

Reference

1. Jackson, K.L., Liang, Y., Hanley, R.P., *et al.* Compounds for the degradation of mutant BRAF. *C4 Therapeutics, Inc.* **WO2025/096858A1** (2025).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM